Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency

Cancer Research

Volumn 68, Issue 21, 2008, Pages 8928-8937

  Gros, Alena ^a   Martínez Quintanilla, Jordi ^a   Puig, Cristina ^a   Guedan, Sonia ^a   Molleví, David G ^a   Alemany, Ramon ^a   Cascallo, Manel ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOLYTIC VIRUS;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG POTENCY; ENDOPLASMIC RETICULUM; EXPERIMENTAL NEOPLASM; FIBROBLAST; GENE ISOLATION; GENE MUTATION; GENE SEQUENCE; GENETIC SELECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGENY; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR XENOGRAFT; VIRUS HYBRID; VIRUS MUTATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL LINE; HUMANS; MICE; MUTAGENESIS; MUTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY;

EID: 55349119141     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1145     Document Type: Article

References (51)

1. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17.
2. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007;28:42-58.
3. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24:7802-16.
4. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299-312.
5. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:1498-504.
6. Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006;14:107-17.
7. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000;81:2605-9.
8. Bernt KM, Ni S, Gaggar A, et al. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 2003;8:746-55.
9. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15:1157-66.
10. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996;334:1185-7.
11. Cascallo M, Alonso MM, Rojas JJ, et al. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007;15:1607-15.
12. Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003;14:425-33.
13. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003;63:1317-24.
14. Doronin K, Toth K, Kuppuswamy M, et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000;74:6147-55.
15. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002;62:6165-71.
16. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999;59:410-3.
17. Bristol JA, Zhu M, Ji H, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003;7:755-64.
18. Yan W, Kitzes G, Dormishian F, et al. Developing novel oncolytic adenoviruses through bioselection. J Virol 2003;77:2640-50.
19. Subramanian T, Vijayalingam S, Chinnadurai G. Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 2006;80:2000-12.
20. Villanueva A, Garcia C, Paules AB, et al. Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-78.
21. Batra SK, Metzgar RS, Worlock AJ, Hollingsworth MA. Expression of the human MUC1 mucin cDNA in a hamster pancreatic tumor cell line HP-1. Int J Pancreatol 1992;12:271-83.
22. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001;8:1347-53.
23. Williams JF, Gharpure M, Ustacelebi S, McDonald S. Isolation of temperature-sensitive mutants of adenovirus type 5. J Gen Virol 1971;11:95-101.
24. Cascallo M, Gros A, Bayo N, et al. Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses. Hum Gene Ther 2006;17:929-40.
25. Cox JH, Bennink JR, Yewdell JW. Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J Exp Med 1991;174:1629-37.
26. Tollefson AE, Scaria A, Saha SK, Wold WS. The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J Virol 1992;66:3633-42.
27. Burchiel SW, Edwards BS, Kuckuck FW, et al. Analysis of free intracellular calcium by flow cytometry: multiparameter and pharmacologic applications. Methods 2000;21:221-30.
28. Jackson MR, Nilsson T, Peterson PA. Retrieval of transmembrane proteins to the endoplasmic reticulum. J Cell Biol 1993;121:317-33.
29. Pahl HL, S ester M, Burgert HG, Baeuerle PA. Activation of transcription factor NF-κB by the adenovirus E3/19K protein requires its ER retention. J Cell Biol 1996;132:511-22.
30. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 1996;220:152-62.
31. Hermiston TW, Tripp RA, Sparer T, Gooding LR, Wold WS. Deletion mutation analysis of the adenovirus type 2 E3-19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J Virol 1993;67:5289-98.
32. Sester M, Burgert HG. Conserved cysteine residues within the E3/19K protein of adenovirus type 2 are essential for binding to major histocompatibility complex antigens. J Virol 1994;68:5423-32.
33. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 1999;162:5049-52.
34. White E, Grodzicker T, Stillman BW. Mutations in the gene encoding the adenovirus early region 1B 19,000-molecular-weight tumor antigen cause the degradation of chromosomal DNA. J Virol 1984;52:410-9.
35. Tollefson AE, S c aria A, Ying B, Wold WS. Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells. J Virol 2003;77:7764-78.
36. Scaria A, Wold WS. Fine-mapping of sequences that suppress splicing in the E3 complex transcription unit of adenovirus. Virology 1994;205:406-16.
37. Gonzalez ME, Carrasco L. Viroporins. FEBSLet t 2003;552:28-34.
38. van Kuppeveld FJ, Hoenderop JG, Smeets RL, et al. Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J 1997;16:3519-32.
39. Pilder S, Logan J, Shenk T. Deletion of the gene encoding the adenovirus 5 early region 1b 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA. J Virol 1984;52:664-71.
40. Andersson M, Paabo S, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985;43:215-22.
41. Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985;41:987-97.
42. Bhat BM, Wold WS. A small deletion distant froma splice or polyadenylation site dramatically alters pre-mRNA processing in region E3 of adenovirus. J Virol 1987;61:3938-45.
43. Chami M, Oules B, Paterlini-Brechot P. Cytobiological consequences of calcium-signaling alterations induced by human viral proteins. Biochim Biophys Acta 2006;1763:1344-62.
44. de Jong AS, Schrama IW, Willems PH, et al. Multimerization reactions of coxsackievirus proteins 2B, 2C and 2BC: a mammalian two-hybrid analysis. J Gen Virol 2002;83:783-93.
45. Gonzalez ME, Carrasco L. The human immunodeficiency virus type 1 Vpu protein enhances membrane permeability. Biochemistry 1998;37:13710-9.
46. Guinea R, Carrasco L. Influenza virus M2 protein modifies membrane permeability in E. coli cells. FEBS Lett 1994;343:242-6.
47. McSharry BP, Burgert HG, Owen DP, et al. Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. J Virol 2008;82:4585-94.
48. Akusjarvi G. Proteins with transcription regulatory properties encoded by human adenoviruses. Trends Microbiol 1993;1:163-70.
49. Alonso MM, Cascallo M, Gomez-Manzano C, et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 2007;67:8255-63.
50. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
51. Hasebe T, Sasaki S, Imoto S, Ochiai A. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000;156:1701-10.